Tag: 100-200

Kim, Ju Yeong; Yi, Myung-Hee; Kim, Myungjun; Yeom, Joon-Sup; Yoo, Hyun Dong; Kim, Seong Min; Yong, Tai-Soon published an article in 2022, the title of the article was Diagnosis of Balamuthia mandrillaris encephalitis by thymine-adenine cloning using universal eukaryotic primers.Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione And the article contains the following content:

Identifying the causal pathogen of encephalitis remains a clin. challenge. A 50-yr-old man without a history of neurol. disease was referred to our department for the evaluation of an intracranial lesion observed on brain magnetic resonance imaging (MRI) scans, and the pathol. results suggested protozoal infection. We identified the species responsible for encephalitis using thymine-adenine (TA) cloning, suitable for routine clin. practice. We extracted DNA from a paraffin-embedded brain biopsy sample and performed TA cloning using two universal eukaryotic primers targeting the V4-5 and V9 regions of the 18S rRNA gene. The recombinant plasmids were extracted, and the inserted amplicons were identified by Sanger sequencing and a homol. search of sequences in the National Center for Biotechnol. Information Basic Local Alignment Search Tool. The infection was confirmed to be caused by the free-living amoeba Balamuthia mandrillaris. Two of 41 colonies recombinant with 18S V4-5 primers and 35 of 63 colonies recombinant with the 18S V9 primer contained B. mandrillaris genes; all other colonies contained human genes. Pathogen-specific PCR ruled out Entamoeba histolytica, Naegleria fowleri, Acanthamoeba spp., and Toxoplasma gondii infections. This is the first report of B. mandrillaris-induced encephalitis in Korea based on mol. identification. TA cloning with the 18S rRNA gene is a feasible and affordable diagnostic tool for the detection of infectious agents of unknown etiol. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to thymine adenine balamuthia mandrillaris encephalitis infection diagnosis, 18s rrna, amoeba, balamuthia mandrillaris, encephalitis, ta cloning, Mammalian Pathological Biochemistry: Nervous System and Psychiatric Diseases and other aspects.Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On December 31, 2015, Meshcheryakova, S. A.; Kataev, V. A.; Fattakhova, I. Ya.; Nikolaeva, K. V.; Bulgakov, A. K. published an article.Category: pyrimidines The title of the article was Synthesis and Antimicrobial Activity of Thietanylpyrimidin-2,4(1H,3H)-Dione Acetanilides and Acetylhydrazones. And the article contained the following:

Alkylation of 6-methyl-1-(thietan-3-yl)pyrimidine-2,4(1H,3H)-dione with chloroacetanilides yielded N-acetanilide derivatives Interaction of 2-4-methyl-2,6-dioxo-3-thietan-3-yl-3,6-dihydropyrimidin-1(2H)-acetohydrazide with carbonyl compounds was used to synthesize arylaldehyde and ketone N-acetylhydrazones. The antimicrobial and antifungal activities of the compounds synthesized here were studied. The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Category: pyrimidines

The Article related to thietanylpyrimidindione acetanilide acetylhydrazone preparation antimicrobial agent, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 28, 2019, Chen, Chen published a patent.Computed Properties of 175357-98-9 The title of the patent was Preparation of cyclic iminopyrimidine derivatives as B-Raf V600E kinase inhibitors. And the patent contained the following:

The invention relates to cyclic iminopyrimidine compounds and their bicyclic derivatives of formula I and their preparation, useful in treating proliferation disorders such as cancer or tumors or for diseases or disorders related to the dysregulation of kinase such as, but not limited to B-Raf V600E kinase. Compounds of formula I are claimed, in which X1, X2, X3, Y1, Y2, and Y3 are each independently N and (un)substituted CH; Z1 is O, S, and (un)substituted NH and CH2; Z2 is bond and NH and derivatives; m = 0-3, n = 1-3; R1-R3 are each independently H, halo, CN, NO2, (un)substituted C1-6 alkyl, etc.; R4 is H and C1-6 alkyl; or pharmaceutically acceptable salts, solvates, or isotopic derivatives thereof. Example compound II was prepared via a multistep process (procedure given). Invention compounds were evaluated for their B-Raf V600E kinase inhibitory activity. From the assay, it was determined that II exhibited growth inhibition of 50% (GI50) at <100 nM. The experimental process involved the reaction of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine(cas: 175357-98-9).Computed Properties of 175357-98-9

The Article related to cyclic iminopyrimidine dihydroimidazoquinazoline preparation kinase inhibition, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Computed Properties of 175357-98-9

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Borodkin, Gennady I.; Elanov, Innokenty R.; Gatilov, Yury V.; Shubin, Vyacheslav G. published an article in 2016, the title of the article was Promotional effect of ionic liquids in electrophilic fluorination of methylated uracils.Related Products of 626-48-2 And the article contains the following content:

A novel efficient protocol has been developed for fluorination of methylated uracils involving a stoichiometric amount of ionic liquid (IL) in alcs. The fluorination of 6-methyluracil and 1,3,6-trimethyluracil has been carried out using the electrophilic fluorinating reagent Selectfluor (F-TEDA-BF4) in MeOH and EtOH solvents with the formation of 5-fluoro-6-methyluracil, 5-fluoro-1,3,6-trimethyluracil as well as α-fluoromethoxy- and α-fluoroethoxy ethers of difluorodihydrouracils as the main products. The use of a stoichiometric amount of ionic liquid as an additive results in acceleration of the reaction. It has been found that the effect of the anion of the IL on the rate of the reaction is more pronounced compared to that of the cation, the effectiveness of the anions decreasing in the following order: [HSO4-] > [OTf-] ~[NTf2-] > [BF4-] > [PF6-]. The influence of metal carbonates on the yields of fluorouracils has also been evaluated. The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Related Products of 626-48-2

The Article related to fluorouracil preparation green chem, electrophilic fluorination ionic liquid, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Related Products of 626-48-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On May 10, 2022, Zhang, Xuejun; Chang, Shaohua; Lei, Sijun; Ding, Xiaohua; Chen, Haomin; Jing, Zhenzhong; Yang, Chengbing; Liu, Lifei; Yang, Jun; Li, Lie published a patent.Name: 2-Chloro-5-isopropylpyrimidine The title of the patent was Preparation of nitrogen-substituted heterocyclic thiophenes and their uses in preparation of a medicament for the treatment of LPAR-related diseases. And the patent contained the following:

The present invention relates to the preparation of nitrogen-substituted heterocyclic thiophenes and their uses in preparation of a medicament for the treatment of LPAR-related diseases. In particular, the nitrogen-substituted heterocyclic thiophene compound I (wherein, R1 = -H, -CN, halogen, -Z-Ra, the following groups (un)substituted by Rb: C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkylamino, C1-6 alkoxy; Z = single bond, -O-, -S- or -CO-; Ra is = C1-6 alkyl, C1-6 alkyl substituted by halogen, amino, C1-3 alkylamino; Rb = -CN, halogen, C1-6 alkyl, C1-6 alkoxy groups; R2 = -H, -CN, halogen, -Y-Rd, the following groups (un)substituted by Re: C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkylamino, C1-6 alkoxy; Y = single bond or -O-, -S-; Rd = C1-6 alkyl, C1-6 alkyl group substituted by halogen; Re = -CN, halogen, C1-6 alkyl, C1-6 alkoxy groups). Further, ( X1, X2, X3 = C or N, and X1, X2, X3 = not N at the same time; Rg is selected from H, F, Cl, methyl; L1 = single bond, -N(R3)- or -O-; L2 = single bond, -O-, C1-6 alkylene (un)substituted by C1-3 alkyl, unsubstituted or cyclopropyl substituted by C1-3 alkyl; R3 = -H, C1-3 alkyl; R4 = -H, -CN, halogen, the following groups (un)substituted by Rh: C1-6 alkyl, C3-8 cycloalkyl; and Rh = -H, halogen, C1-6 alkyl, C1-6 alkyl substituted by halogen, C1-6 alkoxy substituted by halogen groups) was prepared The compound of the present invention has good antagonism to LPAR1, and has good antagonism to LPAR3. The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Name: 2-Chloro-5-isopropylpyrimidine

The Article related to nitrogen substituted heterocyclic thiophene preparation lpar antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Name: 2-Chloro-5-isopropylpyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On October 16, 2002, Bhattacharya, Samit Kumar; Kath, John Charles; Morris, Joel published a patent.Category: pyrimidines The title of the patent was Preparation of substituted bicyclo[]-4-amino-pyridopyrimidine derivatives as kinase inhibitors. And the patent contained the following:

Title compounds I [R1-2 = H, alkyl; R3 = (CR1R2)mR4; m = 0-6 or NR1R3 = (CR1R2)n-indol(in)yl; n = 0-2; X = N and Y is CR9 or X = CR9 and Y = N; R9 = fused-ring bicyclic, bridged bicyclic or spirobicylic group] were prepared For instance, 4-chloro-6-fluoropyrido[3,4-d]pyrimidine (preparation given) was reacted with [3-methyl-4-(pyridin-3-yloxy)phenyl]amine (t-BuOH/ClCH2CH2Cl, reflux, 1 h) and the product coupled to (3-azabicyclo[3.1.0]hex-6-yl)carbamic acid tert-Bu ester (EtOH, sealed tube, 105°, 24 h) and finally deprotected to give II. Selected compounds of the invention had IC50 in the range of 1 nM to 1 pM for erbB-2 receptor kinase. I are used for the treatment of hyperproliferative disorders. The experimental process involved the reaction of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine(cas: 175357-98-9).Category: pyrimidines

The Article related to bicyclic amino pyridopyrimidine erbb2 kinase inhibitor preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 17, 2016, Jonckers, Tim Hugo Maria; Mc Gowan, David Craig; Raboisson, Pierre Jean-Marie Bernard; Embrechts, Werner Constant Johan; Guillemont, Jerome Emile Georges published a patent.HPLC of Formula: 89792-07-4 The title of the patent was Preparation of pyrrolopyrimidines for the treatment of influenza virus infection. And the patent contained the following:

Title compounds I [X = N or C (optionally substituted with -CN, -CF3, -CONH2, etc.); R1 = H or CH3; R2 = H or NH2; R3 = carboxy-substituted alkyl, carboxy-substituted cycloalkyl, -N-alkylsulfone, etc.; or stereoisomeric forms, pharmaceutically acceptable salts, solvates, or polymorphs thereof] were prepared For example, reaction of 2,4-dichloro-5-fluoropyrimidine with cis-N-(3-aminocyclohexyl)pyrrolidine-1-carboxamide/DIPEA followed by Pd(PPh3)4-catalyzed coupling reaction with 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine and deprotection using NaOMe afforded compound II. In anti-influenza activity test against A/Taiwan/1/86 (H1N1) virus, IC50 value of II was 0.005 μM. The experimental process involved the reaction of 2-Methyl-7H-pyrrolo[2,3-d]pyrimidine(cas: 89792-07-4).HPLC of Formula: 89792-07-4

The Article related to pyrrolopyrimidine preparation influenza virus infection treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.HPLC of Formula: 89792-07-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 21, 2017, Liu, Shuangwei published a patent.Quality Control of 2-Methyl-7H-pyrrolo[2,3-d]pyrimidine The title of the patent was Process for preparation of pyrrolo[2,3-d]pyrimidine derivative for treating rheumatoid arthritis. And the patent contained the following:

The invention relates to preparation of pyrrolo[2,3-d]pyrimidine derivative of formula I, wherein R is Me, CF3, F, Ph for treating rheumatoid arthritis. Compound I was prepared via bromination of 2-Me-7-H-pyrrolo[2,3-d]pyrimidine followed by carboxylation, acylation, condensation and reaction with morpholine. The medicine has obvious therapeutic action to RA, and can be used for treating rheumatoid arthritis. The experimental process involved the reaction of 2-Methyl-7H-pyrrolo[2,3-d]pyrimidine(cas: 89792-07-4).Quality Control of 2-Methyl-7H-pyrrolo[2,3-d]pyrimidine

The Article related to pyrrolopyrimidine derivative preparation rheumatoid arthritis, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Quality Control of 2-Methyl-7H-pyrrolo[2,3-d]pyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On September 26, 2017, Deng, Zeping; Chen, Fangjun published a patent.Computed Properties of 1187830-46-1 The title of the patent was Method for synthesizing pyrrolopyrimidine hydrochloride. And the patent contained the following:

The title method for synthesizing 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride comprises reaction of furano[3,4-d]pyrimidine-5,7-dione, followed by reduction and salt formation. The experimental process involved the reaction of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride(cas: 1187830-46-1).Computed Properties of 1187830-46-1

The Article related to synthesis pyrrolopyrimidine hydrochloride imidation reduction, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Computed Properties of 1187830-46-1

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On October 23, 1997, Bridges, Alexander James; Denny, William Alexander; Dobrusin, Ellen Myra; Doherty, Annette Marian; Fry, David W.; Mcnamara, Dennis Joseph; Showalter, Howard Daniel Hollis; Smaill, Jeffrey B.; Zhou, Hairong published a patent.Reference of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine The title of the patent was Preparation of N-quinazolinylacrylamides and analogs as tyrosine kinase inhibitors. And the patent contained the following:

Title compounds [I; R = (CHR6)pR9; R1R2 = CH:CR7CR8:CH, CH:CR7CR8:N, CH:CR7N:CH, etc.; R6 = H or alkyl; 1 of R7,R8 = Z1Z2R10 and the other = OR4, SR4, NHR3; R3,R4 = (un)substituted alkyl, heterocyclylalkyl, etc.; R9 = (un)substituted Ph; R10 = CR11:CHR5, CCR5, CR11:C:CHR5; R5 = H, halo, alkyl, Ph, etc.; R11 = H, halo, alkyl; Z1 = bond, O, (alkyl)imino, CH2, etc.; Z2 = CO, SO, P(O)(OH), etc.; p = 0 or 1] were prepared Thus, I (R = C6H4Br-3, R1R2 = CH:NCR8:CH, R8 = F) was condensed with 3-morpholinoprpanamine and the product acylated by CH2:CHCOCl to give title compound II. Data for biol. activity of I were given. The experimental process involved the reaction of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine(cas: 175357-98-9).Reference of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine

The Article related to quinazolinylacrylamide preparation tyrosine kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Reference of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia